ACRS Profile
Aclaris Therapeutics Inc (ACRS) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for dermatological and immuno-inflammatory diseases. ACRS aims to discover, develop, and deliver first-in-class therapies based on new insights into the molecular mechanisms underlying skin and immuno-inflammatory disorders.
ACRS has a diversified pipeline of drug candidates, including its lead product candidate, ATI-450, a novel oral small molecule inhibitor of RORĪ³t for the treatment of moderate-to-severe psoriasis, and ATI-1777, a topical drug candidate for the treatment of moderate-to-severe atopic dermatitis. ACRS also has several early-stage programs targeting other immuno-inflammatory diseases.
The company's proprietary discovery platform utilizes its expertise in kinase biology to identify and validate novel targets and develop drug candidates that selectively inhibit these targets. The platform is designed to enable rapid and efficient discovery of new drug candidates with optimized pharmacology and safety profiles.
ACRS was founded in 2012 and is headquartered in Wayne, Pennsylvania.
|
